Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial-Reference-Cited by-同舟云学术

Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

Published:2017-06-23 Issue:1 Volume:15 Page:
ISSN:1477-7525
Container-title:Health and Quality of Life Outcomes
language:en
Short-container-title:Health Qual Life Outcomes

Author:

Devlin Nancy,Herdman Michael,Pavesi Marco,Phung De,Naidoo Shevani,Beer Tomasz M.,Tombal Bertrand,Loriot Yohann,Ivanescu Cristina,Parli Teresa,Balk Mark,Holmstrom Stefan

Funder

Astellas Pharma US

Medivation

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12955-017-0704-y.pdf

Reference35 articles.

1. Sandblom G, Carlsson P, Sennfält K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer. 2004;90:1163–8.

2. Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2007;16:571–5.